Merck’s KEYTRUDA approved to treat PD-L1-positive tumor patients

By Nikita Chaurasia  Date: 2020-08-26

Merck’s KEYTRUDA approved to treat PD-L1-positive tumor patients

U.S.-based multinational pharmaceutical giant Merck & Co. Inc. recently announced that its anti-PD-1 therapy named as KEYTRUDA, has received approvals from Japan Pharmaceuticals as well as from Medical Devices Agency (PMDA).

As per the trusted sources, KEYTRUDA monotherapy is approved to treat patients suffering tumors that are PD-L1-positive and have radically unresectable, recurrent or advanced esophageal squamous cell carcinoma (ESCC).

It is to be noted that KEYTRUDA is an anti-PD-1 therapy that improves body’s immune system and also detects and counters tumor cells. The therapy was initially approved to be used at prescribed dosage of 400 mg every six weeks (Q6W), which is operates as an intravenous infusion over 30 minutes across all adult indications, including combination therapy and KEYTRUDA monotherapy, sources claimed.

Dr. Jonathan Cheng, Vice President of oncology clinical research, Merck Research Laboratories reportedly stated that the company is focusing on improving results for as many cancer patients as possible including those with esophageal squamous cell carcinoma, which is a major reason for cancer-related deaths in Japan.

Cheng further added that by using KEYTRUDA the adult patients will now have the provision of a dosing schedule that helps in decreasing the tumor based on how frequently they are at the clinic for treatment.

Jannie Oosthuizen, President at MSD Japan mentioned that over 90% of esophageal cancers are squamous cell carcinomas. Patients who are suffering from advanced disease face poor prognosis and have a critical requirement of better treatment options, he further claimed.

According to the reliable sources, KEYTRUDA’s approval for 400 mg for every six weeks is based on exposure-response analyses and pharmacokinetic modeling. The interim analysis was reportedly based on the pharmacokinetic modeling data, as well as on safety and efficacy data from KEYNOTE-555 which was gathered from a cohort of patients (Cohort B) who use KEYTRUDA 400 mg Q6W.

Source credits-

https://www.merck.com/news/mercks-keytruda-pembrolizumab-receives-two-new-approvals-in-japan/

About Author

Nikita Chaurasia     aeresearch.net

Nikita Chaurasia

An accomplished professional in the field of content development, playing with words comes naturally to Nikita Chaurasia. After completing her post-graduate MBA degree in Advertising and PR, Nikita worked across numerous content-driven verticals, undertaking diverse r...

Read More

More News By Nikita Chaurasia

TCS, Infosys, Accenture workforce to receive free Covid-19 vaccination

TCS, Infosys, Accenture workforce to receive free Covid-19 vaccination

By Nikita Chaurasia

Information technology giants Infosys, Accenture India, and Tata Consultancy Services will reportedly cover Covid-19 vaccination costs for their employees and their family, who are eligible and opt to receive the jab. This news comes along the heels...

Motorola Solutions to offer Norwegian Health Emergency Service with CRS

Motorola Solutions to offer Norwegian Health Emergency Service with CRS

By Nikita Chaurasia

Motorola Solutions has announced to have been selected by Helsetjenestens Driftsorganisasjon for Nødnett HF (HDO HF) to offer the Norwegian Health Emergency Service with a new CRS (Command Central Control Room Solution). Confirming the news,&...

Nestle India exploring options to directly sell products to consumers

Nestle India exploring options to directly sell products to consumers

By Nikita Chaurasia

Nestle India Ltd. is reportedly exploring their options of trying their hands at direct selling since consumers are largely turning towards the internet to purchase products ranging from staples to medicines amidst the COVID-19 pandemic. While the n...

Razorpay: New funding en route, meteoric rise in market value expected

Razorpay: New funding en route, meteoric rise in market value expected

By Nikita Chaurasia

Indian startup Razorpay is reportedly in discussions with Singapore-based sovereign wealth fund GIC Pvt. Ltd. and other existing investors to raise around USD 200 million in a funding round that would allow the fintech company to double its valuation...

FDA to allow pharma companies modify COVID-19 shots amid variants surge

FDA to allow pharma companies modify COVID-19 shots amid variants surge

By Nikita Chaurasia

With the rising cases of Coronavirus variants, the United States Food & Drug Administration (FDA) has reportedly introduced guidelines for pharmaceutical companies to modify their COVID-19 vaccine doses in an effort to curb the spread of the dise...